Abstract Library

#2091 Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors

Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) are insufficient due to poor knowledge of these tumours. Despite showing differentiated features, NETs often exhibit therapeutic resistance to common treatments similarly to other cancers. Although signalling abnormalities have been reported, molecular mechanisms responsible for this resistance phenomenon are yet to be understood.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Romano D, Gerard C, Poizat F, Niccoli P, Barlier A,

Keywords: neuroendocrine tumors, drug resistance, proteomics, kinases, apoptosis,

#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures

Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Romano D

Authors: Mohamed A, Romano D, Poizat F, Delpero J, Niccoli P,

Keywords: pNETs primary culture, everolimus, somatostatin analogues, cell viability, chromogranin A secretion, Akt activity,